Orthogonal Thinker
Private Company
Company Overview
Orthogonal Thinker's platform approach allows shareholders to benefit from the revenues of multiple holdings and subsidiaries. The company envision a future where "farmaceutical" products will usher in a new period of health and wellness based on psychoactive compounds and clean label products.
The company's Ei.ventures subsidiary plans to purchase a vertically-integrated clinical lab and facility that will be home to future clinical trials and compound formulations. The subsidiary's initial focus is on a phase one trial for Psilly, a psychedelic product that emphasizes the use of clean and natural formulations from whole plants versus biosynthetic methods that the industry traditionally uses.
The company's Ei.ventures subsidiary plans to purchase a vertically-integrated clinical lab and facility that will be home to future clinical trials and compound formulations. The subsidiary's initial focus is on a phase one trial for Psilly, a psychedelic product that emphasizes the use of clean and natural formulations from whole plants versus biosynthetic methods that the industry traditionally uses.
Management Team
David Nikzad
Founder & Chairman
Jason A. Hobson
Co-Founder & CEO
Michelle Valentin
Chief Food Formulator
Alexander Speiser
Chief Operating Officer
Nate Sumbot
General Counsel